TRB Wealth Management LLC Purchases Shares of 1,538 Stryker Corporation $SYK

TRB Wealth Management LLC purchased a new position in Stryker Corporation (NYSE:SYK) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 1,538 shares of the medical technology company’s stock, valued at approximately $484,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Brighton Jones LLC increased its position in shares of Stryker by 15.4% in the 4th quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock valued at $1,643,000 after acquiring an additional 609 shares during the period. Schnieders Capital Management LLC. purchased a new stake in Stryker during the 2nd quarter valued at about $205,000. Marshall Wace LLP grew its stake in Stryker by 107.9% during the 2nd quarter. Marshall Wace LLP now owns 5,700 shares of the medical technology company’s stock valued at $2,255,000 after purchasing an additional 77,831 shares during the last quarter. Nebula Research & Development LLC acquired a new position in shares of Stryker in the second quarter valued at about $219,000. Finally, HUB Investment Partners LLC acquired a new position in shares of Stryker in the second quarter valued at about $253,000. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Stryker News Summary

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker’s long-term outlook remains supported by steady demand for its medical technologies, continued Mako robotics growth and improving margins. The company’s latest quarter exceeded expectations, with earnings of $3.69 per share on $6.59 billion in revenue, while revenue increased 9.4% year over year. Here’s Why You Should Hold Stryker Stock in Your Portfolio for Now
• Positive Sentiment: Wall Street remains broadly constructive: consensus calls for a “Moderate Buy” rating, with 18 analysts recommending Buy or Strong Buy versus six Holds. The average target of $386.28 implies meaningful upside from recent trading levels, although several firms have lowered their individual targets. Are Wall Street Analysts Predicting Stryker Stock Will Climb or Sink?
• Neutral Sentiment: Stryker maintained its fiscal 2026 earnings guidance of $14.95 to $15.10 per share and recently declared a quarterly dividend of $0.88, equivalent to a 1.1% annual yield. Institutional ownership remains high at approximately 77%, indicating continued support from large investors.
• Negative Sentiment: Director Ronda Stryker sold a combined 350,000 shares for approximately $117.8 million across August 18–19. Although she still owns more than 2.25 million shares, the transactions reduced her direct ownership and may raise caution among investors. Stryker Director Sells Shares
• Negative Sentiment: Recent commentary highlights execution risks, including cyber and supply-chain disruptions, while analysts have trimmed targets after an imperfect second quarter. BTIG reduced its target to $358 and JPMorgan lowered its target to $350, contributing to near-term pressure despite their Buy and Overweight ratings. Stryker Sell-Off Analysis

Analyst Ratings Changes

SYK has been the subject of a number of research reports. Wall Street Zen raised Stryker from a “hold” rating to a “buy” rating in a report on Saturday, August 8th. Needham & Company LLC cut their price target on shares of Stryker from $454.00 to $418.00 and set a “buy” rating on the stock in a report on Friday, May 1st. JPMorgan Chase & Co. reduced their price target on shares of Stryker from $400.00 to $350.00 and set an “overweight” rating for the company in a research report on Friday, July 31st. The Goldman Sachs Group restated a “neutral” rating and set a $361.00 price objective on shares of Stryker in a research note on Friday, May 1st. Finally, Truist Financial upped their price objective on shares of Stryker from $330.00 to $340.00 and gave the company a “hold” rating in a report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, Stryker has a consensus rating of “Moderate Buy” and an average target price of $386.28.

Insiders Place Their Bets

In other news, insider Debra King sold 826 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total transaction of $277,783.80. Following the sale, the insider owned 6,210 shares of the company’s stock, valued at $2,088,423. This trade represents a 11.74% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Ronda E. Stryker sold 50,000 shares of Stryker stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $340.10, for a total transaction of $17,005,000.00. Following the transaction, the director directly owned 2,251,375 shares of the company’s stock, valued at approximately $765,692,637.50. This trade represents a 2.17% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 665,370 shares of company stock worth $216,238,501. Corporate insiders own 4.60% of the company’s stock.

Stryker Stock Performance

Shares of SYK stock opened at $329.86 on Friday. The stock has a market cap of $126.52 billion, a PE ratio of 34.18, a price-to-earnings-growth ratio of 2.09 and a beta of 0.76. The business has a 50-day simple moving average of $326.99 and a 200-day simple moving average of $332.64. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59. Stryker Corporation has a 52-week low of $281.00 and a 52-week high of $396.86.

Stryker (NYSE:SYK) last issued its earnings results on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, topping analysts’ consensus estimates of $3.49 by $0.20. The firm had revenue of $6.59 billion for the quarter, compared to the consensus estimate of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The company’s revenue was up 9.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, equities analysts expect that Stryker Corporation will post 15.02 EPS for the current year.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be given a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 1.1%. The ex-dividend date is Wednesday, September 30th. Stryker’s dividend payout ratio is currently 36.48%.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.